Navigation Links
Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
Date:10/17/2007

Decision Facilitates European Trial Opening in 13 New Sites

BERKELEY HEIGHTS, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the French Health Products Safety Agency ("AFSSAPS") has granted authorization to open the Company's Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, its lead anticancer compound, in patients with advanced melanoma. This authorization enables the opening of approximately 13 new investigative sites over the next 2-4 weeks.

Genta's Phase 3 trial, known as AGENDA, is a randomized, double-blind, placebo-controlled study in which patients are randomly assigned to receive Genasense plus dacarbazine (DTIC) or DTIC alone. AGENDA will accrue approximately 300 patients and will be conducted at approximately 100 sites worldwide, including North America, Europe and Australia. Accrual, which is currently ongoing, is currently expected to complete in the fourth quarter of 2008.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodi
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, announced ... from Hercules Technology Growth Capital, Inc. (NYSE: ... final advance under the Loan and Security Agreement that ... , Alimera Sciences Limited, entered into with Hercules in ...
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:9/30/2014)... has been awarded a three-year $1.7 million grant ... develop new imaging technologies and data analysis techniques ... networks of neurons in the brain interact to ... identify the precise interactions between millions of nerve ... and alterations in these interactions that may be ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... option to help diabetics curb their sweet tooth, but ... Nature this September, suggests that zero-calorie sweeteners may ... 2 diabetes. , The Weizmann Institute of Science ... fed artificial sweeteners to mice, the mice developed glucose ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set to open ... RMS welcomes the launch of an entirely new facility, ... new treatment center for the Lung Institute. , ... Nashville, the hope is to bring awareness to those ... undiagnosed. With Nashville being a hub for medical technology, ...
(Date:9/30/2014)... Sept. 30, 2014 (HealthDay News) -- Medicare should cover ... high risk for the disease, a coalition of more ... coalition, which includes the Lung Cancer Alliance, the Society ... American Cancer Society and the American Society of Clinical ... to the U.S. Centers for Medicare & Medicaid Services ...
(Date:9/30/2014)... Chicago, IL (PRWEB) September 30, 2014 ... meet at the National Association of Health Advocacy Consultants ... of Healthcare Advocacyā€¯ (#NAHAC14) to be held October 30th ... Making its debut at NAHAC14: Standards and Best Practices ... advocacy grows into a profession, advocates have needed a ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... 2012 - VIB researcher Diether Lambrechts, associated with KU ... which patients will benefit more from treatment with bevacizumab ... step towards personalized medicine and patient-tailored use of this ... Leuven) said "in two large clinical studies with patients ...
... symptoms of heart disease already have heart damage, according to ... Heart Failure Congress 2012 , 19-22 May, in Belgrade, Serbia. ... Failure Association of the European Society of Cardiology., ... research has shown that obese adults have structural and functional ...
... Reinberg HealthDay Reporter , FRIDAY, May 18 (HealthDay News) ... Americans born between 1945 and 1965 -- the baby boom generation ... deadly disease occur in this age group, and most were infected ... the agency said. "CDC views this as an unrecognized health ...
... combination of three drugs used worldwide as the standard of ... of death or hospitalization, and should not be used together ... the surprising results of a rigorous independent study. The ... New England Journal of Medicine to coincide with a ...
... For more than three decades, researchers have warned of ... tobacco smoke (ETS), especially among children whose parents smoke. ... University of Arizona reports that those health risks persist ... individuals end up becoming smokers later in life. ...
... , SATURDAY, May 19 (HealthDay News) -- More than ... more than half of those victims are younger than age ... (May 20 to 26), the American Academy of Pediatrics is ... Postal Service to educate people about dog safety. They ...
Cached Medicine News:Health News:Biomarker predicts response to cancer treatment 2Health News:Obese adolescents have heart damage 2Health News:Test Baby Boomers for Hepatitis C, Says CDC 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 3Health News:Study says children exposed to tobacco smoke face long-term respiratory problems 2Health News:Study says children exposed to tobacco smoke face long-term respiratory problems 3Health News:Keeping Your Family Safe From Dog Bites 2
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
... Seven digital models cover the range from ... liquid fluently. Volume lock design prevents inadvertent ... the horizontal grip. Whole pipette is autoclavable ... ejector is all polypropylene. Suitable for one-handed ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: